Jubilant Life Sciences receives ANDA approval for 0.9% Sodium Chloride Injection USP

Jubilant Life Sciences’ subsidiary Jubilant HollisterStier LLC, Spokane, Washington, has received Abbreviated New Drug Application (ANDA) approval for 0.9% Sodium Chloride Injection USP, 3 mL and 10 mL vials, the generic equivalent of Sodium Chloride 0.9% in Plastic Container, of Hospira, Inc., which is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered.

This is the first ANDA approval in injectables received by the company. The company has filed two injectables and one ophthalmic product as on March 31, 2016.

Jubilant Life Sciences is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.